“Black boxes” and survival; Mixed news for new drugs; Does a positive attitude help?

Open the “black boxes” of cancer survivorship care. (UC Riverside, Social sciences and medicine)

Advanced age and smoking were the two most important factors for the 5-year risk of developing any type of cancer. (American Cancer Society, Cancer)

A review of FDA approvals of new cancer drugs over a period of nearly 20 years showed substantial benefits for progression-free survival, but minimal effect on overall survival. (Journal of Clinical Oncology)

A phase III trial of pembrolizumab (Keytruda) plus chemotherapy for metastatic castration-resistant prostate cancer showed no improvement in overall survival or radiographic progression-free survival compared with chemotherapy alone, Merck announced.

Metformin failed to ameliorate adverse effects of androgen deprivation therapy on body weight, waist circumference, and other metabolic parameters in men with locally advanced prostate cancer. (International Journal of Radiation Oncology, Biology and Physics)

A phase I/II trial evaluating the addition of cetuximab (Erbitux) to chemoradiotherapy for non-muscle invasive bladder cancer showed evidence of short-term disease control before being discontinued due to of a slow accumulation. (BJU International)

The Civica Hospital-owned pharmaceutical company has started selling a generic version of the popular prostate cancer drug abiraterone (Zytiga), the company’s latest effort to shake up the pharmaceutical industry and bring down drug prices. (the wall street journal)

Does a positive attitude affect cancer outcomes? (Journal of Clinical Oncology)

The Environmental Protection Agency is warning residents who live near medical sterilization plants emitting ethylene oxide in more than a dozen states of an increased risk of cancer.

Public health messages focused on urinary symptoms of prostate cancer can hamper early detection efforts. (Bloomberg)

Innate Pharma has announced that an AstraZeneca-sponsored phase III trial of the monoclonal antibody monalizumab plus cetuximab for advanced squamous cell carcinoma of the head and neck has reached the breaking point of futility.

The FDA’s final regulatory guidelines recommend including patients with incurable cancers in clinical trials, even when patients meet exclusion criteria.

Belgium-based Celyad Oncology announced that the FDA has lifted a clinical hold on a Phase Ib of the company’s NKG2D CAR T-cell allogeneic therapy plus pembrolizumab (Keytruda) for treatment-refractory, stable/recovery microsatellite metastatic colorectal cancer. mismatches.

For the first time in nearly a decade, fewer people made serious efforts to quit smoking in 2020, coinciding with the peak of the COVID-19 pandemic. (American Cancer Society, JAMA Open Network)

  • Charles Bankhead is editor for oncology and also covers urology, dermatology and ophthalmology. He joined MedPage Today in 2007. Follow

Comments are closed.